{"id":"oxybutinin-extended-release","safety":{"commonSideEffects":[{"rate":"29-72%","effect":"Dry mouth"},{"rate":"7-15%","effect":"Constipation"},{"rate":"5-17%","effect":"Dizziness"},{"rate":"1-15%","effect":"Blurred vision"},{"rate":"7-26%","effect":"Headache"},{"rate":"1-14%","effect":"Somnolence"}]},"_chembl":{"chemblId":"CHEMBL2108492","moleculeType":"Protein"},"_fixedAt":"2026-03-30T18:37:18.652272","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By antagonizing M3 muscarinic receptors on detrusor muscle, oxybutynin decreases the frequency and amplitude of bladder contractions. The extended-release formulation provides sustained drug delivery over 24 hours, improving tolerability and compliance compared to immediate-release formulations. This mechanism reduces urinary urgency, frequency, and incontinence episodes in patients with overactive bladder.","oneSentence":"Oxybutynin is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:14.085Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with symptoms of urge incontinence, urgency, and frequency"},{"name":"Neurogenic detrusor overactivity in spinal cord injury patients"}]},"_fixedFields":["modality→Biologic"],"trialDetails":[{"nctId":"NCT01557244","phase":"PHASE3","title":"A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-07-02","conditions":"Urinary Bladder, Neurogenic","enrollment":181},{"nctId":"NCT01796548","phase":"PHASE4","title":"Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity","status":"TERMINATED","sponsor":"Janssen-Cilag Ltd.,Thailand","startDate":"2008-12","conditions":"Detrusor Function, Overactive","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lyrinel"],"phase":"marketed","status":"active","brandName":"Oxybutinin Extended-Release","genericName":"Oxybutinin Extended-Release","companyName":"Janssen-Cilag Ltd.,Thailand","companyId":"janssen-cilag-ltd-thailand","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxybutynin is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency, Neurogenic detrusor overactivity in spinal cord injury patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}